Breast cancer. Malignant neoplasm of breast, endocrine therapy, neoadjuvant
Conditions
Interventions
Intervention 1: Intervention group: Neoadjuvant patients treated with doxorubicin chemotherapy (60mg / m2) and cyclophosphamide (2600mg / m 2) every 2 weeks for 4 cycles, followed by paclitaxol (175mg
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: female with invasive breast cancer with positive hormone receptor and negative HER2 proven in pathology Clinical Phase IIA to IIIC (T1-4, N0-3, M0) Age more than 18 years Good performance ((ECOG: 0-1 No history of previous chemotherapy It is a conscientious informed consent
Exclusion criteria
Exclusion criteria: Pregnancy / Breastfeeding Liver cirrhosis History of thromboembolic events in the patient History of osteoporotic fractures Patient's lack of cooperation in correct implementation of the treatment process in accordance with the recommended guidelines
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical response rate. Timepoint: Clinical examination before and after treatment of Neo-adjuvant. Method of measurement: clinical examination and Sonography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pathologic response. Timepoint: after surgery. Method of measurement: pathologic response rate. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Mozaheb
Mashhad University of Medical Sciences
Outcome results
None listed